Top > Search of International Patents > Hollow nanoparticle of NBsAg large protein for drug delivery

Hollow nanoparticle of NBsAg large protein for drug delivery achieved

Foreign code F110005560
File No. P023P03US
Posted date Sep 8, 2011
Country United States of America
Application number 50924903
Gazette No. 20060088536
Gazette No. 7951379
Date of filing Mar 26, 2003
Gazette Date Apr 27, 2006
Gazette Date May 31, 2011
International application number JP2003003694
International publication number WO2003082330
Date of international filing Mar 26, 2003
Date of international publication Oct 9, 2003
Priority data
  • P2002-097424 (Mar 29, 2002) JP
  • P2003-045088 (Feb 21, 2003) JP
  • 2003WO-JP03694 (Mar 26, 2003) WO
Title Hollow nanoparticle of NBsAg large protein for drug delivery achieved
Abstract (US7951379)
The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue.
The effectiveness of the drug has been proved by animal testing.
The invention also provides a therapeutic method using such a drug.
In a drug according to the present invention, a substance to be transferred into a cell for treating a disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein that has been modified to lack its infectivity to hepatocytes and display an antibody).
The particle surface of the drug displays an antibody, such as a cancer specific antibody, that recognizes an antigen molecule displayed on the surface of a specific cancer cell.
Scope of claims [claim1]
1. A hollow nanoparticle for delivering a substance to a cell, comprising a modified HBV surface antigen large (HBsAg L) protein formed into a particle, an antibody displayed on the surface of the particle, and a substance encapsulated inside the particle, wherein the modified HBsAg L protein includes a replacement of amino acids 50 to 153 in a pre-S region of the HBsAg L protein, corresponding to HBV serotype y, by a ZZ tag consisting of SEQ ID NO: 29, and wherein the antibody binds to the ZZ tag fused to the HBsAg L protein.
[claim2]
2. The hollow nanoparticle of claim 1, wherein the antibody is a single chain antibody.
[claim3]
3. The hollow nanoparticle of claim 1, wherein the modified HBsAg L protein is expressed in a eukaryotic cell.
[claim4]
4. The hollow nanoparticle of claim 3, wherein the eukaryotic cell is selected from a group consisting of a yeast cell, an insect cell, and an animal cell.
[claim5]
5. The hollow nanoparticle of claim 1, wherein the substance comprises a gene.
[claim6]
6. The hollow nanoparticle of claim 5, wherein the gene comprises a gene of thymidine kinase derived from simplex herpes virus.
[claim7]
7. A hollow nanoparticle comprising a modified HBV surface antigen large (HBsAg L) protein formed into a particle, wherein the modified HBsAg L protein includes a replacement of amino acids 50 to 153 in a pre-S region of the HBsAg L protein, corresponding to HBV serotype y, by a ZZ tag consisting of SEQ ID NO: 29.
  • Inventor, and Inventor/Applicant
  • KURODA SHUNICHI
  • TANIZAWA KATSUYUKI
  • OKAJIMA TOSHIHIDE
  • KONDO AKIHIKO
  • UEDA MASAKAZU
  • SENO MASAHARU
  • BEACLE VIB - VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
IPC(International Patent Classification)
U.S. Cl./(Sub)
  • A61K009/51H8B
  • A61K047/48T4B28
  • A61K047/48W8D
  • A61K048/00B4B
  • B82Y005/00
  • C07K014/005
  • C07K016/18
  • C07K016/28G
  • C07K016/40
  • C12N007/00
  • C12N015/88
  • K61K039/555B5
  • M07K317/622
  • M12N730/10122
  • M12N730/10123
  • M12N810/85G
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close